Fig. 1From: Cardiovascular surrogate markers and cardiometabolic therapeutics: a viewpoint learned from clinical trials on dipeptidyl peptidase-4 inhibitorsTesting the cardiovascular potentials of drugs through surrogate markersBack to article page